Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in Western countries. Although the prognosis of patients with many types of cancer has improved recently due to advances in diagnostic and therapeutic modalities, the outlook for patients with PDAC still remains dismal with a median survival of just 6 months from diagnosis and an overall 5-year survival rate of less than 5% ([Warshaw and Fernandez-del Castillo, 1992](#bib48){ref-type="other"}; [Murr *et al*, 1994](#bib33){ref-type="other"}; [Jemal *et al*, 2005](#bib26){ref-type="other"}). Many previous studies have attempted to elucidate the molecular mechanisms underlying pancreatic tumorigenesis, but it is still not fully understood. Therefore, a better understanding of the genes involved in tumour growth and progression is necessary for the development of novel diagnostic and therapeutic strategies that could improve the outcome of this deadly disease.

Array-based comparative genomic hybridisation (array CGH) is a powerful technique that has been used to detect DNA copy number alterations across the entire genome of malignant tumours ([Solinas-Toldo *et al*, 1997](#bib44){ref-type="other"}; [Pinkel *et al*, 1998](#bib36){ref-type="other"}; [Pollack *et al*, 1999](#bib37){ref-type="other"}; [Albertson *et al*, 2000](#bib2){ref-type="other"}; [Snijders *et al*, 2001](#bib43){ref-type="other"}; [Fiegler *et al*, 2003](#bib6){ref-type="other"}). Compared to conventional CGH, the significantly improved resolution of array CGH permits highly accurate mapping of DNA copy number changes throughout the genome. In cancer, genomic alterations contribute to dysregulation of the expression levels of oncogenes and tumour suppressor genes, the accumulation of which is correlated with tumour progression ([Ried *et al*, 1999](#bib38){ref-type="other"}). Therefore, array CGH provides a promising starting point for the identification of novel candidate genes affected by such genomic imbalances. Several array CGH investigations of PDAC have already been reported, but all these studies were performed on cell lines or whole tissue samples ([Aguirre *et al*, 2004](#bib1){ref-type="other"}; [Heidenblad *et al*, 2004](#bib18){ref-type="other"}; [Holzmann *et al*, 2004](#bib20){ref-type="other"}; [Mahlamaki *et al*, 2004](#bib31){ref-type="other"}; [Bashyam *et al*, 2005](#bib3){ref-type="other"}; [Gysin *et al*, 2005](#bib13){ref-type="other"}; [Nowak *et al*, 2005](#bib34){ref-type="other"}). In cell lines, culture-induced genetic adaptation may be induced during the establishment of cell lines in *in vitro* conditions. On the other hand, PDAC tissues are characterised by a desmoplastic reaction, with neoplastic cells constituting only a small proportion of the tumour mass. Therefore, cytogenetic analysis using bulk tissue samples is invariably hampered by contamination with non-neoplastic cells.

The aim of this study is to identify novel genetic abnormalities that precisely reflect the characteristics of tumour cells *in vivo*. For this purpose, we applied array CGH to 23 microdissected PDAC tissue samples that consist of purified populations of cancer cells. Then, a subset of identified genetic alterations was evaluated in an independent sample set of 19 PDAC cases using fluorescence *in situ* hybridisation (FISH) analysis. Finally, *in situ* RNA hybridisation (ISH) and reverse transcription--PCR (RT--PCR) were performed to assess whether the identified genetic alteration could lead to significant change in transcript level of the gene in question.

MATERIALS AND METHODS
=====================

Tissue samples
--------------

A total of 23 fresh-frozen PDAC specimens were obtained surgically or at autopsy from Yamaguchi University School of Medicine, Japan, with appropriate ethical approval ([Table 1](#tbl1){ref-type="table"}). All the tissues were confirmed histologically by a pathologist. Tissue microdissection was performed manually to collect more than 90% of tumour cells in all the cases as described previously ([Harada *et al*, 2002a](#bib16){ref-type="other"}). Briefly, only cancerous regions were microdissected using a sterile 26-gauge needle from several serial tissue sections (20 *μ*m thickness) under visualisation with an inverted microscope (Nikon 66906, Tokyo, Japan). DNA was extracted from at least 5000 tumour cells according to the standard protocol. Reference DNA was obtained from lymphocytes of both healthy male and female volunteers. In addition, another series of 19 formalin-fixed, paraffin-embedded tumour sections (4 *μ*m thickness) were provided from Yamaguchi University (*n*=10) and Tohoku University School of Medicine, Japan (*n*=9), for FISH and ISH analyses ([Table 1](#tbl1){ref-type="table"}). Owing to the limited accessibility of clinical specimens, the samples used in array CGH were not available for FISH and ISH. For RT--PCR, 16 fresh-frozen PDAC tissues and two normal pancreas tissues were obtained from the Human Biomaterials Resource Centre, Department of Histopathology, Charing Cross Hospital, London, UK, with full ethical approval of the host institution. The clinicopathological information was not available for these anonymous samples. Haematoxylin--eosin-stained slides were examined to ensure a content of 60--80% tumour cells before use and then, total RNA was extracted directly from homogenised tissues using TRIZOL (Invitrogen Ltd, Paisley, UK).

CGH arrays and image acquisition
--------------------------------

The whole-genome CGH arrays were produced at the Wellcome Trust Sanger Institute and consist of 3125 BAC/PAC clones that cover the entire human genome at 1 Mb resolution ([Fiegler *et al*, 2003](#bib6){ref-type="other"}). All the clone details are available on the Ensembl genome browser (v39, June 2006; <http://www.ensembl.org/Homo_sapiens/index.html>).

Array CGH was performed as described previously, with minor modifications ([Fiegler *et al*, 2003](#bib6){ref-type="other"}; [Hurst *et al*, 2004](#bib21){ref-type="other"}). Briefly, tumour and reference DNAs (300 ng) were labelled with Cy5-dCTP and Cy3-dCTP, respectively. Hybridisation was carried out at 37°C for 36 h in a hybridisation chamber (GeneMachines, San Carlos, CA, USA). After washing the slides, fluorescence intensities were measured on an Axon 4000B scanner (Axon Instruments Inc., Burlingame, CA, USA) and the raw images were analysed using the GenePix Pro 4.0 software (Axon). Duplicate hybridisations were performed for each sample to verify the reproducibility of the data except for one case (PC5). The correlation coefficients were calculated on the normalised tumour channel and observed to range from 0.63 to 0.90 (data not shown).

Statistical and data analysis
-----------------------------

The CGH arrays were read with the UCSF 'SPOT\' software to produce raw text files ([Jain *et al*, 2002](#bib25){ref-type="other"}). These files were read into R and normalised (using the loess intensity-dependent method), using the 'limma\' package ([Smyth, 2005](#bib42){ref-type="other"}; [The R Development Core Team, 2006](#bib46){ref-type="other"}); background correction was omitted in this case, as visual inspection showed it increased the scatter in both the MA and chromosomal-location plots, and the correlation statistics were worse with background subtraction, indicative of low levels of background on the slides being misestimated. The log~2~-transformed normalised data were then pre-processed to average any on-slide replicates using the 'snapCGH\' package from Bioconductor and segmented into local regions of constant copy number by circular binary segmentation ([Gentleman *et al*, 2004](#bib10){ref-type="other"}; [Olshen *et al*, 2004](#bib35){ref-type="other"}). The sample levels (two replicates for each tumour per clone) were summarised by means to give tumour-level data (one measurement per clone for each tumour). These data were then used in a linear model that estimated the fold change across the tumours, along with a *P*-value that the average log~2~-fold change between the tumour channel and the normal channel was non-zero (for both the normalised data and the locally smoothed data -- data not shown for the latter). Clones that had an uncorrected *P*-value below 0.001 were considered to be significant candidates.

Two-colour FISH
---------------

Four human BAC clones (RP11-403N12, RP11-232C20, RP11-8H2 and RP11-350K6) were purchased from BACPAC Resources (Oakland, CA, USA) and these DNAs were labelled with Cy3-dCTP using BioPrime Array CGH Genomic Labeling System (Invitrogen). Centromeric probes for chromosomes 7 and 18 (CEP7 and 18), labelled with SpectrumGreen, were purchased from Vysis (Downers Grove, IL, USA). The specificity of all the probes was confirmed by hybridisation onto Normal Male Metaphase (Vysis).

Two-colour FISH was performed as described previously ([Lu *et al*, 1999](#bib29){ref-type="other"}). DNA copy number was evaluated for each probe by counting spots in at least 100 nuclei. A ratio was calculated between the average copy number of the BAC probes and of corresponding centromeric probes. Based on hybridisation in 10 normal pancreatic tissues (acinar and ductal cells), the threshold of gain and loss was defined as the ratios of \>1.16 (+2 standard deviation (s.d.)) and \<0.87 (−2 s.d.), respectively (data not shown). Our approach was to use normal samples to estimate overall noise levels: choosing the threshold on the tumour samples corresponding to a ±2 s.d. of the normal samples indicates a roughly 5% false-positive rate if the tumour samples were commensurate with diploidy.

*In situ* RNA hybridisation for *SEC11L3*
-----------------------------------------

The *SEC11L3* probe was amplified by PCR from OriGene clone TC123085 (OriGene Technologies, Inc., Rockville, MD, USA) that encodes full-length cDNA of *SEC11L3*. The primers used to amplify a 216-bp *SEC11L3* product are as follows: forward 5′-TTGGATATCTTCGGGGACCT-3′ and reverse 5′-GTCTTCCCGGAAATTTGTGA-3′. The PCR product was cloned into the pCR4-TOPO vector using the TOPO cloning kit (Invitrogen) to create pCR4-*SEC11L3*-ISH. Positive clones were verified by sequence analysis. The pCR4-*SEC11L3*-ISH plasmid was linearised with *Pst*I for the sense probe and *Not*I for the antisense probe. After removing restriction endonucleases, riboprobes were synthesised from 1 *μ*g of template DNA and digoxigenin (DIG) were labelled using a DIG RNA labeling kit (Roche Diagnostics GmbH, Mannheim, Germany). T3 and T7 polymerases were used to synthesise antisense probes and sense probes, respectively. DIG incorporation of riboprobes was verified by DOT blot with anti-digoxigenin-AP Fab fragments (Roche). Antisense and sense riboprobes for *SEC11L3* were hybridised to 19 tissue sections using the Ventana Discovery System with Ventana Ribomap and Bluemap kits. Expression of *SEC11L3* mRNA in cancer cells was compared to that of non-neoplastic epithelial cells (ductal, acinar, intestinal and hepatic cells) on the identical specimen and judged using a 0--2 score (0=no staining, 1=weak intensity, 2=intensity comparable to non-neoplastic counterparts).

Reverse transcription--PCR for *SEC11L3*
----------------------------------------

cDNAs were synthesised from 1 *μ*g of total RNA using an oligo dT primer and the Multiscribe reverse transcription kit (Applied Biosystems, Warrington, Cheshire, UK) as instructed by the manufacturer. Reverse transcription was followed by 30 PCR cycles (1 min of denaturation at 94°C, 1 min of annealing at 55°C and 1 min of extension at 72°C). Primers for *SEC11L3* are the same as those designed in ISH. Primers for 18S ribosomal RNA, which was used as an endogenous control for normalisation, are as follows: forward 5′-CGCCGCTAGAGGTGAAATTC-3′ and reverse 5′-CATTCTTGGCAAATGCTTTCG-3′. Amplified products were separated on 1% agarose gels and visualised with ethidium bromide.

RESULTS
=======

Comparison of array CGH profiles in microdissected tissues and cell lines
-------------------------------------------------------------------------

A total of 23 microdissected PDAC tissues were analysed by array CGH. Applying highly stringent statistical conditions (*P*\<0.001), we could identify the regions of nonrandom genomic changes in PDAC. [Figure 1](#fig1){ref-type="fig"} shows overall copy number changes for each chromosome and the entire data set of all clones is available in [Supplementary Table 1](#sup1){ref-type="other"} (the raw data set for all the experiments is shown in [Supplementary Table 2](#sup1){ref-type="other"}). A total of 1015 clones met the statistical criterion; 17% of clones (508 clones including 698 candidate genes) showed genetic gain and 17% (507 clones including 1254 genes) showed loss. The array CGH profiles were compared to the previous reports in which PDAC-derived cell lines were analysed ([Aguirre *et al*, 2004](#bib1){ref-type="other"}; [Bashyam *et al*, 2005](#bib3){ref-type="other"}; [Gysin *et al*, 2005](#bib13){ref-type="other"}; [Nowak *et al*, 2005](#bib34){ref-type="other"}). Although they displayed similar spectrum patterns of genetic alterations overall, we found that there were apparently different breakpoints in our profiles. Our data showed several segmented gains on chromosome 2, which have rarely been observed in cell lines. In contrast, losses of 4q and 13q and gains of 11q and 20q in cell lines were not as frequent as in our microdissected samples. Next, we focused on individual clones harbouring the genes that are known to be dysregulated in cell lines. Increased copy numbers were detected in the regions including *MYC* (8q24.21) and *NCOA3/AIB1* (20q13.12), while genetic losses were observed in the regions containing *SMAD4* (18q21.1), *TP53* (17p13.1), *MAP2K4* (17p11.2) and *RUNX3* (1p36.11). However, using the rigorous statistical conditions employed, we identified neither genetic gains of *KRAS* (12p12.1), *MYB* (6q23.3), *EGFR* (7p11.2) and *ERBB2* (17q12) nor losses of *MLH1* (3p22.2), *BRCA2* (13q13.1) and *CDH1* (16q22.1). (All the genes cited here are depicted in [Figure 1](#fig1){ref-type="fig"}.)

Contiguous regions of nonrandom copy number changes
---------------------------------------------------

In addition to numerous localised alterations, we detected a total of 41 contiguous regions (\>3.0 Mb) of nonrandom genomic changes ([Table 2](#tbl2){ref-type="table"}). For instance, increased copy number was detected in the 26.0 Mb region of 7p22.2--p15.1 that contains 48 known or hypothetical protein-coding genes. We also defined the regions of genetic gains on 1q, 3q, 5p, 5q, 8q and 12p, which may represent loci for candidate oncogenes in PDAC. The largest region of copy number loss was from 17p13.3 to 17p12 (13.6 Mb), which covers a total of 53 candidate genes including *TP53* (17p13.1) as well as *MAP2K4* (17p11.2). We delineated three contiguous regions of genomic loss on 18q, which is known to be a site of frequent deletions in PDAC, 18q21.2--q22.1 (12.0 Mb), 18q22.3--q23 (7.1 Mb) and 18q12.3--q21.2 (6.9 Mb). The region of 18q21.2--q22.1 harbours 16 candidate genes in addition to *SMAD4* (18q21.1) that is one of the most recurrently inactivated tumour suppressor genes in PDAC. The region of 18q12.3--q21.2 contains a total of 23 putative target genes, whereas seven genes are included in the 7.1 Mb region of 18q22.3--q23. Interestingly, the clone encompassing *DCC* (18q21.2) has shown an apparent discontinuity between two broad regions of genetic loss (18q12.3--q21.2 and 18q21.2--q22.1) in our 23 microdissected PDAC sample set ([Figure 1](#fig1){ref-type="fig"}).

Verification of genetic changes by two-colour FISH
--------------------------------------------------

To investigate prospectively whether the identified genetic abnormalities are prevalent in PDAC, interphase FISH analysis was performed using an independent sample set ([Figure 2](#fig2){ref-type="fig"}). Previous cytogenetic studies have shown that chromosome arms 7p and 18q may include oncogenes and tumour suppressor genes that play a critical role in pancreatic carcinogenesis ([Griffin *et al*, 1995](#bib12){ref-type="other"}; [Hahn *et al*, 1995](#bib15){ref-type="other"}; [Fukushige *et al*, 1997](#bib9){ref-type="other"}, [1998](#bib8){ref-type="other"}; [Mahlamaki *et al*, 1997](#bib30){ref-type="other"}; [Schleger *et al*, 2000](#bib41){ref-type="other"}; [Harada *et al*, 2002a](#bib16){ref-type="other"}; [Iacobuzio-Donahue *et al*, 2004](#bib24){ref-type="other"}). Therefore, we prioritised three regions (7p22.3--p15.1, 18q12.3--q21.2 and 18q21.2--q22.1) of nonrandom copy number changes detected in array CGH and a subset of four BAC clones (RP11-403N12 at 7p21.1, RP11-232C20 at 7p15.2, RP11-8H2 at 18q21.1 and RP11-350K6 at 18q21.32) were selected from those regions ([Table 3](#tbl3){ref-type="table"}). As shown in [Table 4](#tbl4){ref-type="table"}, deletion in the locus encompassing *SEC11L3* (18q21.32) was observed to be the most recurrent alteration (13 out of 19 samples; 68%) ([Figure 2B](#fig2){ref-type="fig"}). The region 18q21.1 defined by RP11-8H2 was deleted in 11 out of 19 cases (58%) and contains three known candidate genes: *ATP5A1*, *PSTPIP2* and *CCDC5*. RP11-403N12 including *BCMP11* (7p21.1) showed an increased copy number in 10 out of 19 cases (53%) ([Figure 2C](#fig2){ref-type="fig"}), whereas gain of the region at RP11-232C20 containing *SCAP2* (7p15.2) was demonstrated in seven out of 19 cases (37%) ([Figure 2D](#fig2){ref-type="fig"}).

*SEC11L3* mRNA downregulation detected by ISH and RT--PCR
---------------------------------------------------------

Subsequently, the *SEC11L3* mRNA level was evaluated by ISH ([Figure 3](#fig3){ref-type="fig"}). Firstly, we tested several different types of normal epithelial cells from the pancreas, intestine and liver. Normal pancreatic tissues showed strong mRNA expression of *SEC11L3* in both ductal and acinar cells (score 2), whereas there was weak expression in islet cells (score 1). Strong expression was also observed in normal intestinal and hepatic cells (score 2). Of 19 PDAC cases, *SEC11L3* mRNA was downregulated (score 0--1) in 11 cases (58%), whereas it was unchanged (score 2) in eight cases (42%) ([Table 4](#tbl4){ref-type="table"}). All 11 cases with downregulated *SEC11L3* demonstrated genetic losses by FISH. Despite decreased copy numbers, *SEC11L3* was expressed in two samples (PC46 and PC51). A significant correlation between deletion and expression levels was found (*P*=0.001, Fisher\'s exact test), indicating that the mRNA level of this gene was highly dependent on its DNA copy number.

RT--PCR was performed further to confirm downregulated mRNA of *SEC11L3* in PDAC. [Figure 4](#fig4){ref-type="fig"} shows *SEC11L3* expression in normal pancreas and PDAC tissue samples. Compared to two normal pancreas tissues, *SEC11L3* was found to be downregulated in 16 out of 16 PDAC samples (100%). In particular, the *SEC11L3* transcript was virtually almost absent in four PDAC tissues (25%; lane 5, 6, 7 and 15).

DISCUSSION
==========

It is well known that a strong desmoplastic reaction is a typical feature of PDAC tissues. A dense stromal component, which occupies larger parts of the tumour mass, significantly reduces the sensitivity and specificity of cytogenetic analysis. Tissue microdissection is laborious, but the practical method available to enrich the tumour cell population in clinical specimens. In the present study, we first identified genomic abnormalities that represent the characteristics of tumour cells *in vivo* by combining CGH arrays with tissue microdissection. This approach led to more precise definition of chromosomal breakpoints in a panel of 23 PDAC tissue samples. To identify nonrandom genomic changes in PDAC, we applied a *P*-value rather than a fixed cutoff value because we found that concomitant lack of power in dichotomising the data at an early stage in the analysis provided poor resolution with which to distinguish between clones. Taking a statistical threshold approach allows us to take account of different clones\' differing variance across samples that a fixed fold-change approach does not.

We compared the CGH profiles to the previously published cell line data ([Karhu *et al*, 2006](#bib27){ref-type="other"}). Despite overall similar spectrum patterns, there were clear differences between both profiles. It is important to take into account that the resolution of CGH arrays used and the type of statistical analysis employed vary widely between the reports. However, our results indicated that some recurrent genetic alterations, such as losses of 4q and 13q and gains of 11q and 20q, seem to be relatively unique to cell lines, implying that these genetic changes may have been artificially acquired through the establishment of cell lines or in the course of culturing. In addition, our data did not demonstrate significant copy number changes of some known genes, such as *KRAS*, *ERBB2*, *MLH1* and *CDH1*. This is probably due to the fact that intragenic mutation or promoter methylation is more likely to occur in these genes ([Lemoine *et al*, 1992](#bib28){ref-type="other"}; [Scarpa *et al*, 1994](#bib40){ref-type="other"}; [Rozenblum *et al*, 1997](#bib39){ref-type="other"}; [Ueki *et al*, 2000](#bib47){ref-type="other"}). Alternatively, this discrepancy could be explained by the intratumoral heterogeneity that is characteristically observed in PDAC cells *in vitro* as well as *in vivo*, or may reflect the differences of the geographic origin of the tumours used in this study (a total of 42 Japanese samples were analysed by array CGH, FISH and ISH) ([Scarpa *et al*, 1994](#bib40){ref-type="other"}; [Gorunova *et al*, 1998](#bib11){ref-type="other"}; [Harada *et al*, 2002b](#bib17){ref-type="other"}). Similarly, deletion of the DCC gene was not recurrent in our sample set. However, a larger scale of study using much higher-resolution genome-wide microarrays (tiling-path CGH arrays or single nucleotide polymorphism arrays) is required to conclude whether this genetic alteration is critically involved in the pathogenesis of PDAC.

As our array CGH profiles revealed that the regions of 7p22.2--p15.1, 18q12.3--q21.2 and 18q21.2--q22.1 are nonrandomly altered, four clones from those regions were validated by FISH experiments. The results showed that genetic alterations for these clones were observed in 37--68% of tumours in a separate sample set, supporting the validity of our CGH results. Moreover, copy number changes of those four clones were detected in 18 out of 19 PDAC cases (95%), implying the potential clinical applicability. Among the candidate genes verified by FISH, *BCMP11* is newly detected in PDAC, although [Fletcher *et al* (2003)](#bib7){ref-type="other"} demonstrated that mRNA and protein of this gene were overexpressed in oestrogen receptor-positive breast cancer. This gene lies adjacent to the *AGR2* gene (7p21.1) and both genes are classified as members of the same family (AGR family) due to highly similar (approximately 70%) protein sequences. Interestingly, several gene expression analyses have shown that *AGR2* is upregulated in the majority of PDACs as well as pancreatic intraepithelial neoplasia (PanIN) lesions ([Crnogorac-Jurcevic *et al*, 2003](#bib5){ref-type="other"}; [Iacobuzio-Donahue *et al*, 2003a](#bib22){ref-type="other"}; [Iacobuzio-Donahue *et al*, 2003b](#bib23){ref-type="other"}; [Missiaglia *et al*, 2004](#bib32){ref-type="other"}; [Buchholz *et al*, 2005](#bib4){ref-type="other"}). Taken together, *BCMP11* is also likely to be involved in the development of PDAC. On the other hand, *SCAP2* was first described in a recently published report, showing that mRNA of this gene is frequently overexpressed in PanIN lesions ([Buchholz *et al*, 2005](#bib4){ref-type="other"}). The protein encoded by this gene belongs to the src family of kinases. [Takahashi *et al* (2003)](#bib45){ref-type="other"} demonstrated that *SCAP2* functions as a downstream target of c-Src under various stress conditions (UV light, tumour necrosis factor-*α* and osmotic stress). Therefore, *SCAP2* also seems to work as a cell-signalling molecule in cancer cells. However, the biological function and putative role of these two genes have not been investigated in cancer.

Remarkably, *SEC11L3* was deleted in approximately 70% of tumours and its expression level was significantly correlated with its DNA copy number. Despite the high frequency of this genetic abnormality, this gene has not been described in any type of cancer. Previous cytogenetic analyses have revealed a frequent deletion of 18q in PDAC, but neither the chromosomal breakpoints nor the candidate genes included could be clearly identified due to technical limitations of the technology employed ([Griffin *et al*, 1995](#bib12){ref-type="other"}; [Hahn *et al*, 1995](#bib15){ref-type="other"}; [Fukushige *et al*, 1997](#bib9){ref-type="other"}, [1998](#bib8){ref-type="other"}; [Mahlamaki *et al*, 1997](#bib30){ref-type="other"}; [Hoglund *et al*, 1998](#bib19){ref-type="other"}; [Schleger *et al*, 2000](#bib41){ref-type="other"}; [Harada *et al*, 2002a](#bib16){ref-type="other"}; [Iacobuzio-Donahue *et al*, 2004](#bib24){ref-type="other"}). *SMAD4* (18q21.1) has been reported to be deleted or inactivated in about 50% of PDACs and, therefore, it is considered to be one of the most likely candidate tumour suppressor genes at this locus ([Hahn *et al*, 1996](#bib14){ref-type="other"}; [Rozenblum *et al*, 1997](#bib39){ref-type="other"}). However, we propose that *SEC11L3* (18q21.32) could be an equally promising candidate gene on 18q because the significance of genetic loss of this gene is comparable to that of the *SMAD4* gene. In addition, both ISH and RT--PCR independently confirmed that *SEC11L3* mRNA is downregulated in PDAC tissues at a high frequency (53% and 100%, respectively), suggesting that dysregulation of this gene is likely to be associated with the development of PDAC. Little is known about the biological role of this gene, although it belongs to the peptidase S26B family and functions as part of the signal peptidase complex.

In summary, we could successfully identify genetic alterations that reflect the intrinsic characteristics of PDAC cells *in vivo* by combining array CGH with tissue microdissection. These results provided a valid data set to search for novel candidate genes involved in pancreatic carcinogenesis. The specificity of our array CGH results was confirmed by interphase FISH in an independent sample set. Among the identified candidates, we are particularly interested in the *SEC11L3* gene that is located on 18q21.32. FISH and ISH analyses for this gene demonstrated a significant correlation between genetic deletion and the corresponding mRNA downregulation, raising the possibility that the *SEC11L3* gene may play a putative role as a tumour suppressor. For these reasons, we propose that *SEC11L3* should be considered as a potential marker gene for the molecular diagnosis of PDAC and a possible candidate target for therapeutic intervention.
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![Summary of overall genome-wide alterations in a total of 23 microdissected PDAC tissues. Genetic gains are shown as green dots and losses as red dots (Y axis) at each clone position along the chromosome (X axis). Several representative clones with no genetic changes are depicted as black dots. Square-shaped dots indicate the clones validated by FISH, whereas triangle dots indicate previously identified genes in PDAC. Vertical dotted lines represent chromosome centromeres.](6603563f1){#fig1}

![Four representative images in FISH analysis. Target BAC DNA probes were labelled with Cy3-dCTP (red), while centromeric probes were labelled with SpectrumGreen. DNA copy number was evaluated for each probe by counting spots in at least 100 nuclei. (**A**) No copy number change of *BCMP11* in PC40. (**B**) Genetic loss of *SEC11L3* in PC48. (**C**) Genetic gains of *BCMP11* in PC44 and (**D**) of *SCAP2* in PC49.](6603563f2){#fig2}

![*SEC11L3* mRNA expression in non-neoplastic epithelial cells and PDAC cells, as determined by ISH. (**A**) Strong expression (score 2) in both ductal (*white arrows*) and acinar cells of non-neoplastic pancreas. (**B**) ISH conducted with a sense *SEC11L3* riboprobe, used as a negative control. (**C**--**E**). No expression (score 0) in PDAC cells (*black arrows*), but weak expression (score 1) in non-neoplastic islet cells (*black arrow heads*) (PC41 and 47) (**F**). Weak expression (score 1) of PDAC cells in PC43 and (**G**) strong intensity of expression (score 2) of PDAC cells in PC44. (**H**) Lower level of expression (score 1; PC53) and (**I**) similar intensity of expression (score 2; PC55) in metastatic PDAC cells (*black arrows*) compared to non-neoplastic hepatic cells (*asterisk*).](6603563f3){#fig3}

![mRNA expression of *SEC11L3* in normal pancreas and PDAC tissues, as determined by RT-PCR. 18S ribosomal RNA was used as an internal standard. Samples were run in the following order: lane 1--2, normal pancreas; lane 3--18, PDACs; lane 19, negative control. *SEC11L3* expression was found to be present in normal pancreas, while it was decreased in 16 out of 16 PDAC tissues (100%).](6603563f4){#fig4}

###### 

The clinicopathological data of PDAC tissue samples

  **Sample**                                                                              **Age**  **Sex**   **Location^a^**   **Histology^b^**    **T**   **N**   **M**  **Stage**
  -------------------------------------------------------------------------------------- --------- --------- ----------------- ------------------ ------- ------- ------- -----------
  *(A) Microdissected fresh-frozen tissue samples used for array CGH (n=23)*                                                                                              
  PC1                                                                                       66     F         P(Ph)             mod                   3       0       0    II
  PC2                                                                                       66     F         P(Pb)             well                  3      1a       0    III
  PC3                                                                                       66     M         P(Ph)             mod                   3      1b       0    III
  PC4                                                                                       59     F         P(Ph)             mod                   3      1b       0    III
  PC5                                                                                       64     M         P(Ph)             mod                   3      1b       0    III
  PC6                                                                                       47     M         P(Ph)             mod                   4      1b       0    IVa
  PC7                                                                                       66     M         P(Ph)             mod                   4      1b       0    IVa
  PC8                                                                                       69     F         P(Ph)             poor                  4      1b       0    IVa
  PC9                                                                                       73     F         P(Ph)             mod                   4      1b       0    IVa
  PC10                                                                                      56     M         P(Pt)             mod                   4      1b       1    IVb
  PC11                                                                                      76     F         P(Ph)             mod                   4      1b       1    IVb
  PC12                                                                                      63     F         P(Pb)             mod                   4      1b       1    IVb
  PC13                                                                                      78     F         P(Pt)             mod                   4      1b       1    IVb
  PC14                                                                                      68     F         P(Ph)             mod                   4      1b       1    IVb
  PC15                                                                                      65     M         P(Pb)             mod                   4      1b       1    IVb
  PC16                                                                                      65     M         P(Ph)             mod                   4      1b       1    IVb
  PC17                                                                                      60     M         P(Ph)             mod                   4      1b       1    IVb
  PC18                                                                                      76     M         P(Ph)             mod                   4      1b       1    IVb
  PC19                                                                                      54     F         P(Pb)             poor                  4      1b       1    IVb
  PC20                                                                                      72     F         P(Pt)             mod                   4      1b       1    IVb
  PC34                                                                                      60     M         LM                mod                   4      1b       1    IVb
  PC35                                                                                      75     M         LM                mod                   4      1b       1    IVb
  PC36                                                                                      67     F         LM                mod                   4      1b       1    IVb
                                                                                                                                                                           
  *(B) Formalin-fixed, paraffin-embedded tissue sections used for FISH and ISH (n=19)*                                                                                    
  PC37                                                                                      74     M         P(Ph)             mod                   2       0       0    I
  PC38                                                                                      72     M         P(Pt)             poor                  3       0       0    II
  PC39                                                                                      70     M         P(Ph)             mod                   3       1       0    III
  PC40                                                                                      58     M         P(Ph)             mod                   3       1       0    III
  PC41                                                                                      69     F         P(Pb)             well                  3       1       0    III
  PC42                                                                                      51     M         P(Ph)             poor                  3       1       0    III
  PC43                                                                                      73     M         P(Ph)             mod                   3       1       0    III
  PC44                                                                                      59     M         P(Pb)             mod                   3       1       0    III
  PC45                                                                                      53     F         P(Ph)             mod                   4       1       0    IVa
  PC46                                                                                      53     M         P(Pb)             mod                   4       1       0    IVa
  PC47                                                                                      56     M         P(Ph)             well                  4       1       0    IVa
  PC48                                                                                      57     F         P(Ph)             mod                   3       1       1    IVb
  PC49                                                                                      65     F         P(Ph)             mod                   3       1       1    IVb
  PC50                                                                                      59     M         P(Ph)             mod                   3       1       1    IVb
  PC51                                                                                      61     M         P(Ph)             mod                   4       1       1    IVb
  PC52                                                                                      74     M         P(Pb)             poor                  4       1       1    IVb
  PC53                                                                                      57     F         LM                mod                   3       1       1    IVb
  PC54                                                                                      61     M         LM                mod                   4       1       1    IVb
  PC55                                                                                      74     M         LM                poor                  4       1       1    IVb

P=primary lesion; Ph=head; Pb=body; Pt=tail of the pancreas; LM=liver metastatic lesion.

mod=moderately; poor=poorly differentiated tubular adenocarcinoma.

PDAC=pancreatic ductal adenocarcinoma; FISH=fluorescence *in situ* hybridisation; ISH=*in situ* RNA hybridisation.

###### 

Contiguous regions (\>3.0 Mb) of chromosomal changes in a total of 23 microdissected PDAC tissues

  **Locus**          **Start (bp)**   **End (bp)**   **Size (Mb)**   **Mean log2**      **Locus**      **Start (bp)**   **End (bp)**   **Size (Mb)**   **Mean log2**
  ----------------- ---------------- -------------- --------------- --------------- ----------------- ---------------- -------------- --------------- ---------------
  1q24.1--q25.1       163 809 021     173 127 283         9.3            0.235        1p35.1--p34.3      34 152 076      38 379 441         4.2           −0.232
  1q25.2--q25.3       177 942 453     181 046 133         3.0            0.208        4p16.2--p16.1      5 094 062       8 313 477          3.2           −0.216
  1q31.1--q31.3       187 406 225     1 957 10 013        8.3            0.255       6p21.32--p21.31     32 031 967      34 013 145         4.0           −0.219
  1q41                215 371 867     219 919 554         4.5            0.242            6q21          108 154 127     112 486 834         4.3           −0.181
  1q42.2--q43         231 700 764     241 495 322         9.8            0.253        6q25.2--q25.3     155 289 734     158 440 778         3.2           −0.204
  2p16.1--p14          60 927 185      64 676 357         4.8            0.171         8p22--p21.3       17 784 184      21 872 595         4.1           −0.264
  2q22.2--q22.3       143 499 638     146 775 971         3.3            0.168        9p24.3--p24.1         190          6 659 690          6.7           −0.228
  2q32.1              185 140 061     188 357 186         3.2            0.161        9p22.1--p21.3      19 310 506      23 557 472         4.2           −0.256
  2q32.3              192 914 919     196 752 218         3.8            0.146       9q22.31--q22.33     94 281 893     100 889 311         6.6           −0.171
  3q26.1              163 532 324     167 501 265         4.0            0.237       9q33.3--q34.11     126 127 921     129 390 787         3.3           −0.216
  5p15.31--p15.2       7 449 057       10 495 937         3.0            0.165       9q34.13--q34.3     133 982 008     137 333 442         3.4           −0.226
  5p14.3--p14.1        20 429 524      28 918 008         8.5            0.232        17p13.3--p12        800 495        14 360 892        13.6           −0.252
  5q11.1--q11.2        50 061 482      54 725 678         4.7            0.174       18q12.3--q21.2      41 216 566      48 119 508         6.9           −0.350
  5q12.2--q13.1        63 325 516      66 888 015         3.6            0.149       18q21.2--q22.1      49 795 841      61 752 947        12.0           −0.252
  5q14.1--q14.3        80 075 105      86 472 400         6.4            0.168        18q22.3--q23       68 809 458      75 940 259         7.1           −0.294
  5q14.3               87 676 680      90 964 362         3.3            0.170       21q21.3--q22.11     29 627 040      34 602 938         5.0           −0.182
  7p22.2--p15.1        2 607 390       28 603 446        26.0            0.207       22q11.22--q12.1     21 400 636      25 896 652         4.5           −0.205
  7p14.1               38 185 228      41 345 287         3.2            0.170        22q12.2-q12.3      28 379 384      31 627 100         3.2           −0.180
  7q21.11              79 539 131      83 414 012         3.9            0.219                                                                                
  8q21.11--q21.13      77 234 275      81 648 851         4.4            0.225                                                                                
  8q21.13--q21.3       82 640 038      89 400 934         6.8            0.271                                                                                
  8q24.11--q24.13     118 297 084     123 697 997         5.4            0.254                                                                                
  12p12.3--p12.1       19 403 674      23 784 534         4.4            0.268                                                                                

PDAC=pancreatic ductal adenocarcinoma.

###### 

Contiguous regions of nonrandom copy number changes on 7p and 18q

  **BAC**           **Region**       **Genes included^a^**   **Overall results**                                                                                        
  ----------------- --------------- ----------------------- --------------------- ------------- ------ ------- ------------------------------ ------------ ------------ --------------
  RP11-106E3        7p22.2                 2 607 390              2 657 138          49 749      26.0     2                *IQCE*                0.134        1.098        0.000242
  RP11-172O13       7p22.1                 5 704 716              5 847 079          142 364              1               *TRIAD3*               0.182        1.135        5.25E-06
  RP1-42M2          7p22.1                 59 69 700              6 049 710          80 011               7           *PMS2, EIF2AK1*            0.165        1.121        0.000272
  RP4-810E6         7p22.1                 6 049 510              6 202 437          152 928              6           *PSCD3, EIF2AK1*           0.220        1.164        1.23E-06
  RP11-425P5        7p22.1                 6 233 987              6 446 613          212 627              4            *RAC1, PSCD3*             0.144        1.105        0.000254
  RP4-733B9         7p22.1-p21.3           7 176 436              7 292 189          115 754              1              *C1GALT1*               0.189        1.140        4.92E-07
  RP11-505D17       7p21.3                 7 947 759              8 125 919          178 161              2            *GLCCI1, ICA1*            0.231        1.174        1.07E-08
  RP11-304A10       7p21.3                 8 950 512              9 040 173          89 662               0                                      0.144        1.105        0.000274
  RP5-959C21        7p21.3                 9 924 891             10 064 840          139 950              0                                      0.143        1.104        6.08E-06
  RP11-352E12       7p21.3                10 064 640             10 151 963          87 324               0                                      0.190        1.141        2.08E-06
  RP11-392P1        7p21.3                10 372 373             10 429 780          57 408               0                                      0.207        1.155        3.66E-08
  RP11-502P9        7p21.3                11 782 368             11 938 707          156 340              0                                      0.254        1.192        5.32E-09
  RP5-1100A7        7p21.3                12 725 574             12 827 381          101 808              0                                      0.226        1.170        9.02E-09
  RP11-195L14       7p21.3                12 951 352             13 077 542          126 191              0                                      0.242        1.183        1.45E-08
  RP4-685A2         7p21.2                13 887 063             13 996 422          109 360              1                *ETV1*                0.278        1.213        5.64E-10
  RP11-512E16       7p21.2                14 128 072             14 279 388          151 317              1                *DGKB*                0.262        1.199        1.75E-09
  RP11-196O16       7p21.1                16 023 294             16 205 465          182 172              2                                      0.182        1.135        8.23E-07
  **RP11-403N12**   **7p21.1**          **16 865 247**         **17 055 918**      **190 672**          **1**           ***BCMP11***           **0.239**    **1.181**    **2.76E-08**
  RP11-323K15       7p21.1                17 781 327             17 929 240          147 914              1               *SNX13*                0.109        1.079        9.16E-05
  RP11-71F18        7p21.1-p15.3          19 406 242             19 580 569          174 328              0                                      0.147        1.107        8.00E-06
  RP11-486P11       7p15.3                20 042 179             20 150 597          108 419              1                *7A5*                 0.317        1.246        1.30E-11
  RP4-701O19        7p15.3                20 884 182             20 950 414          66 233               0                                      0.190        1.140        4.72E-05
  RP11-211J15       7p15.3                21 173 901             21 257 598          83 698               2                                      0.183        1.135        2.43E-07
  RP11-445O1        7p15.3                21 588 234             21 669 042          80 809               1               *DNAH11*               0.210        1.157        9.97E-08
  RP11-451F11       7p15.3                23 714 553             23 804 532          89 980               1               *STK31*                0.346        1.271        1.43E-11
  RP11-343P21       7p15.3                24 511 504             24 521 807          10 304               0                                      0.226        1.169        3.17E-08
  RP11-99O17        7p15.2                25 824 267             25 925 677          101 411              0                                      0.225        1.169        2.79E-07
  **RP11-232C20**   **7p15.2**          **26 765 660**         **26 911 371**      **145 712**          **1**           ***SCAP2***            **0.275**    **1.210**    **1.80E-10**
  RP4-781A18        7p15.2-p15.1          27 976 171             28 166 812          190 642              2             *tcag7.981*              0.181        1.133        1.83E-06
  RP4-596O9         7p15.1                28 459 769             28 603 446          143 678              1               *CREB5*                0.175        1.129        8.62E-06
                                                                                                                                                                               
  RP11-463D17       18q12.3               41 216 566             41 408 713          192 148     6.9      0                                      −0.439       −1.356       1.00E-11
  **RP11-8H2**      **18q21.1**         **41 851 567**         **41 984 947**      **133 381**          **5**   ***ATP5A1, CCDC5, PSTPIP2***   **−0.249**   **−1.189**   **1.50E-07**
  RP11-313C14       18q21.1               423 50 383             42 350 954            572                1               *LOXHD1*               −0.471       −1.386       5.75E-13
  RP11-71F23        18q21.1               43 069 131             43 274 185          205 055              0                                      −0.451       −1.367       2.87E-11
  RP11-46D1         18q21.1               44 393 176             44 552 924          159 749              1              *KIAA0427*              −0.264       −1.201       1.85E-05
  RP11-141E12       18q21.1               45 025 819             4 5187 979          162 161              1                *DYM*                 −0.150       −1.109       0.000150
  RP11-419L16       18q21.1-q21.2         46 310 160             46 473 840          163 681              1               *MAPK4*                −0.378       −1.300       1.02E-06
  RP11-76E22        18q21.2               46 462 730             46 633 371          170 642              2                *MRO*                 −0.393       −1.313       3.94E-10
  RP11-729G3        18q21.2               46 732 284             46 888 494          156 211              4            *SMAD4, ELAC1*            −0.389       −1.309       2.67E-08
  RP11-1E21         18q21.2               47 274 828             47 443 303          168 476              2                                      −0.322       −1.250       2.22E-08
  RP11-25O3         18q21.2               47 958 320             48 119 508          161 189              0                                      −0.346       −1.271       1.64E-06
                                                                                                                                                                               
  RP11-116K4        18q21.2               49 795 841             49 971 830          175 990     12.0     1                *MBD2*                −0.331       −1.258       6.44E-08
  RP11-99A1         18q21.2               50 563 151             50 702 093          138 943              1               *RAB27B*               −0.374       −1.296       4.86E-08
  RP11-397A16       18q21.2               51 445 553             51 648 118          202 566              1                                      −0.263       −1.200       1.58E-07
  RP11-383D22       18q21.31              52 656 265             52 867 730          211 466              2                *WDR7*                −0.179       −1.132       0.000196
  RP11-35G9         18q21.31              53 447 744             53 561 700          113 957              4               *ATP8B1*               −0.195       −1.145       1.99E-06
  RP11-61J14        18q21.32              54 567 090             54 747 580          180 491              6           *ZNF532, MALT1*            −0.223       −1.167       3.87E-07
  **RP11-350K6**    **18q21.32**        **54 867 252**         **55 027 999**      **160 748**          **1**          ***SEC11L3***           −**0.289**   **−1.222**   **5.58E-09**
  RP11-396N11       18q21.32              56 063 594             56 151 592          87 999               0                                      −0.233       −1.176       7.74E-08
  RP11-520K18       18q21.32              56 874 822             57 034w619          159 798              0                                      −0.230       −1.173       1.22E-06
  RP11-13L22        18q21.33              58 408 978             58 578 530          169 553              3               *PHLPP*                −0.320       −1.248       3.63E-11
  RP11-215A20       18q21.33              58 572 412             58 756 503          184 092              2               *PHLPP*                −0.198       −1.147       1.24E-05
  RP11-233O10       18q22.1               59 886 252             59 971 318          85 067               1              *C18orf20*              −0.250       −1.189       2.21E-10
  RP11-389J22       18q22.1               61 594 898             61 752 947          158 050              1                *CDH7*                −0.189       −1.140       8.76E-07
                                                                                                                                                                               
  RP11-169F17       18q22.3               68 809 458             69 000 813          191 356     7.1      0                                      −0.329       −1.256       4.02E-10
  RP11-25L3         18q22.3               69 588 036             69 755 177          167 142              0                                      −0.236       −1.177       8.63E-08
  RP11-556L15       18q22.3               70 753 437             70 931 323          177 887              1               *ZNF407*               −0.348       −1.272       3.55E-09
  RP11-396D4        18q22.3--q23          71 168 342             71 337 306          168 965              1                                      −0.261       −1.198       1.51E-07
  RP11-234N1        18q23                 72 266 630             72 448 118          181 489              2               *ZNF516*               −0.373       −1.295       3.41E-11
  RP11-118I2        18q23                 73 613 846             73 764 173          150 328              0                                      −0.275       −1.210       1.20E-06
  RP11-16L7         18q23                 73 908 671             74 017 409          108 739              0                                      −0.271       −1.206       2.94E-12
  RP11-563B11       18q23                 74 707 626             74 870 951          163 326              1               *SALL3*                −0.294       −1.226       3.81E-07
  RP11-154H12       18q23                 75 586 355             75 701 258          114 904              2               *CTDP1*                −0.321       −1.249       1.20E-08
  CTC-964M9         18q23                 75 939 424             75 940 259            836                0                                      −0.230       −1.173       9.86E-06

The four clones that were used in FISH analysis are outlined in bold.

The size of the contiguous region.

The number of genes included in each clone and examples of candidate genes contained within each clone. All the details are shown in [Supplementary Table 1](#sup1){ref-type="other"}.

###### 

The results of FISH and ISH analyses^a^

  **Clone ID/candidate**    **RP11-403N12**/***BCMP11***   **RP11-232C20**/***SCAP2***   **RP11-8H2**/***ATP5A1***   **RP11-350K6**/***SEC11L3***  
  ------------------------ ------------------------------ ----------------------------- --------------------------- ------------------------------ -------------
  PC37                                  1.05                          0.99                       **0.71**                      **0.83**                **1**
  PC38                                  1.02                          1.12                         0.94                          0.94                    2
  PC39                                  0.98                          1.09                         1.05                        **0.77**                **0**
  PC40                                  1.01                        **1.30**                       0.95                        **0.57**                **1**
  PC41                                  1.13                          0.93                       **0.20**                      **0.46**                **0**
  PC42                                **1.28**                      **1.18**                     **0.56**                        0.91                    2
  PC43                                **1.23**                        0.94                         0.91                        **0.71**                **1**
  PC44                                **1.35**                      **1.52**                     **0.66**                        0.94                    2
  PC45                                  1.01                          1.01                       **0.63**                      **0.71**                **1**
  PC46                                  1.06                          1.13                         0.94                        **0.86**                  2
  PC47                                  0.98                          1.03                       **0.74**                      **0.36**                **0**
  PC48                                **1.59**                        0.94                         0.90                        **0.51**                **0**
  PC49                                **1.17**                      **1.24**                     **0.58**                        1.04                    2
  PC50                                  1.01                          1.03                         0.94                        **0.63**                **0**
  PC51                                **1.24**                      **1.26**                     **0.64**                      **0.82**                  2
  PC52                                **1.25**                        0.97                       **0.85**                        1.11                    2
  PC53                                **1.49**                        1.14                       **0.71**                      **0.70**                **1**
  PC54                                **1.39**                      **1.50**                     **0.51**                      **0.52**                **0**
  PC55                                **1.41**                      **1.50**                       0.95                          1.08                    2
                                                                                                                                                          
  Frequency (%)                     10/19 (53%)                    7/19 (37%)                   11/19 (58%)                  13/19 (68%)            11/19 (58%)

Significant differences are outlined in bold.

FISH=fluorescence *in situ* hybridisation; ISH=*in situ* RNA hybridisation.
